🏛️ Verified NIH Record • Updated 2026-08-18

A Study to Assess the Efficacy, Safety and Pharmacokinetics of EYU688 in Patients With Dengue Fever (NCT06006559)

🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Novartis Pharmaceuticals

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to characterize the effect on dengue viral load, fever clearance time as well as on clinical signs and symptoms with the treatment of EYU688 compared with placebo in patients with dengue fever.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (20 items).

Location: Novartis Investigative Site — Manaus, Amazonas

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • Participants with any of abnormalities of clinical laboratory parameters.
  • Usage of any anticoagulant drugs.
  • Current significant medical conditions or illness that the investigator considers should exclude the participants, especially those that require continuation of other medications likely to have an interaction with the study drug.
  • Pregnant or nursing (lactating) women.
  • Clinical signs and symptoms for severe dengue according to Dengue Guideline (WHO 2009) at screening.
  • Participants with any of the following abnormalities of clinical laboratory parameters at screening:
  • Hemoglobin \<12.0 g/dL in males; \<11.0 g/dL in females
  • Hematocrit \>52 % in males; \>46 % in females
  • Absolute neutrophil count \<1500/μL
  • Platelet count \<80,000/mm3
  • Creatinine \>165 μmol/L in males; \>130 μmol/L in females

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (27 Sites)

  • Novartis Investigative Site — Manaus, Amazonas
  • Novartis Investigative Site — Brasília, Federal District
  • Novartis Investigative Site — Rio de Janeiro, Rio de Janeiro
  • Novartis Investigative Site — Porto Alegre, Rio Grande do Sul
  • Novartis Investigative Site — São Caetano do Sul, São Paulo
  • Novartis Investigative Site — São José do Rio Preto, São Paulo
  • Novartis Investigative Site — Sorocaba, São Paulo
  • Novartis Investigative Site — Barranquilla, Atlántico
  • Novartis Investigative Site — Bucaramanga, Santander Department
  • Novartis Investigative Site — Cali, Valle del Cauca Department
  • Novartis Investigative Site — Belagavi, Karnataka
  • Novartis Investigative Site — Mumbai, Maharashtra
  • Novartis Investigative Site — Pune, Maharashtra
  • Novartis Investigative Site — Jaipur, Rajasthan
  • Novartis Investigative Site — Chennai, Tamil Nadu
  • Novartis Investigative Site — Kuantan, Pahang
  • Novartis Investigative Site — Ipoh, Perak
  • Novartis Investigative Site — Seberang Jaya, Pulau Pinang
  • Novartis Investigative Site — Miri, Sarawak
  • Novartis Investigative Site — Kuala Selangor,
  • Novartis Investigative Site — Oaxaca City,
  • Novartis Investigative Site — Veracruz,
  • Novartis Investigative Site — Singapore, Singapore
  • Novartis Investigative Site — Singapore,
  • Novartis Investigative Site — Haiphong,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
🏛️ View Official NIH Record ↗